Clinical Trial Update: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) [Phase 2]

View source ↗

Summary

A Phase 2 study of ravulizumab in proliferative lupus nephritis and immunoglobulin A nephropathy has been terminated, with results posted in January 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Nephropathy
• Lupus Nephritis

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Status: TERMINATED | Results posted: 2026-01-22